PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Authors
Keywords
-
Journal
Communications Biology
Volume 4, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-08
DOI
10.1038/s42003-021-02191-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
- (2020) Isaure Vanmeerbeek et al. OncoImmunology
- Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
- (2020) Qian Wu et al. ACTA PHARMACOLOGICA SINICA
- Targeting glycosylated PD-1 induces potent anti-tumor immunity
- (2020) Linlin Sun et al. CANCER RESEARCH
- The design and development of covalent protein-protein interaction inhibitors for cancer treatment
- (2020) Sha-Sha Cheng et al. Journal of Hematology & Oncology
- PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
- (2020) Zhengping Hu et al. PLoS One
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy
- (2019) Pottayil G Sasikumar et al. MOLECULAR CANCER THERAPEUTICS
- Cells, drugs and NMR
- (2019) Gregg Siegal et al. JOURNAL OF MAGNETIC RESONANCE
- CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
- (2019) Bogdan Musielak et al. MOLECULES
- In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action
- (2019) Derek J. Blevins et al. ACS Medicinal Chemistry Letters
- V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
- (2019) Stephanie Muller et al. MODERN PATHOLOGY
- 1209PExcellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1
- (2019) V Radhakrishnan et al. ANNALS OF ONCOLOGY
- VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
- (2019) Liju Zong et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
- (2019) Lawrence P. Andrews et al. NATURE IMMUNOLOGY
- Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
- (2018) Markella Konstantinidou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
- (2018) Pottayil G. Sasikumar et al. BIODRUGS
- ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
- (2018) Tim H. Holmström et al. MOLECULAR CANCER THERAPEUTICS
- Cancer immunologists scoop medicine Nobel prize
- (2018) Heidi Ledford et al. NATURE
- Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
- (2017) Katarzyna Guzik et al. JOURNAL OF MEDICINAL CHEMISTRY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
- (2017) Lukasz Skalniak et al. Oncotarget
- The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
- (2017) Christine Böger et al. OncoImmunology
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis
- (2015) L. V. Yuzefovych et al. CANCER RESEARCH
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
- (2015) K. W. Yoon et al. SCIENCE
- Live Cell NMR
- (2014) Darón I. Freedberg et al. Annual Review of Biophysics
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response
- (2013) Daniel Heylmann et al. PLoS One
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412
- (2011) P. S. Romer et al. BLOOD
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More